Akelos Inc.'s Lead Compound Achieves Preclinical Safety Milestone

NEW YORK, March 4, 2021 (Newswire.com) - Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain, announces the lead compound AKE-1018 significantly reduces neuropathic pain in preclinical testing.

Akelos's oral lead compound AKE-1018, at 10-times the lowest effective antihyperalgesic dose tested, does not affect heart rate, blood pressure, motor strength/coordination, is non-sedating, and lacks the potential for abuse. These results provide evidence of an excellent safety profile. AKE-1018 has been previously been shown to significantly reduce hypersensitivity to both mechanical and thermal noxious stimuli. This response was equivalent in both male and female adult rats and was seen as early as with a single dose, and which improved with additional daily dosing over a seven-day period.

Dr. Dianna Willis, Co-Director of the Center for Pain and Sensory recovery at the Burke Neurological Institute (White Plains, NY), Assistant Professor of Neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine (New York, NY) and lead investigator on these studies, observed: "These results clearly support the continued effort to develop AKE-1018 into a novel, non-opiate treatment for peripheral neuropathic pain."

Akelos Inc. is in a research collaboration with Weill Cornell Medicine to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain. Dr. Goldstein is a patent owner and scientific advisory board member of Akelos, Inc.

For more information, please contact:

Akelos Inc.
Dr. Steven Fox, CEO
212-953-1544
[email protected]

Akelos Inc. Forward-Looking Statement: This press release contains forward-looking statements. These forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Akelos, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. These statements include, among others, those related to: the results of research and development activities, uncertainties relating to preclinical and clinical testing, the cost, timing and outcome of the regulatory development and approval process, our budgets, expenditures and financing plans, our need for substantial additional funds, patent and intellectual property matters, our dependence on third parties, including contract research and contract clinical trial organizations; and market opportunity and competition.

The information contained in this press release is believed to be current as of the date of original issue. Akelos, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Source: Akelos Inc.